Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
Clinical trial NCT03179943 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03179943
- Sponsor
- Fox Chase Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-27
- Primary completion
- 2020-07-12
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.